Peapod Lane Capital LLC Acquires Shares of 144,743 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Peapod Lane Capital LLC bought a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the fourth quarter, HoldingsChannel.com reports. The firm bought 144,743 shares of the company’s stock, valued at approximately $806,000.

Other large investors have also recently modified their holdings of the company. nVerses Capital LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $40,000. Values First Advisors Inc. acquired a new position in 4D Molecular Therapeutics during the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after acquiring an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $108,000. Finally, Marquette Asset Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $116,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 0.7 %

Shares of NASDAQ:FDMT opened at $4.55 on Thursday. 4D Molecular Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $36.25. The business has a fifty day simple moving average of $5.69 and a 200 day simple moving average of $9.53.

Analysts Set New Price Targets

A number of research firms recently issued reports on FDMT. Morgan Stanley lowered their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, February 1st. Royal Bank of Canada cut their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.